Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01721057




Registration number
NCT01721057
Ethics application status
Date submitted
1/11/2012
Date registered
2/11/2012
Date last updated
18/09/2019

Titles & IDs
Public title
A Study in Moderate to Severe Rheumatoid Arthritis Participants
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Secondary ID [1] 0 0
I4V-MC-JADX
Secondary ID [2] 0 0
14059
Universal Trial Number (UTN)
Trial acronym
RA-BUILD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Baricitinib
Treatment: Drugs - cDMARD

Placebo Comparator: Placebo - Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.
Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.

Experimental: Baricitinib 2 mg - Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.
Participants will continue to take background cDMARD therapy throughout study.

Experimental: Baricitinib 4 mg - Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.
Participants will continue to take background cDMARD therapy throughout study.


Treatment: Drugs: Placebo
Administered orally

Treatment: Drugs: Baricitinib
Administered orally

Treatment: Drugs: cDMARD
Conventional disease-modifying anti-rheumatic drug as a background therapy
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Timepoint [1] 0 0
Baseline, Week 12
Secondary outcome [2] 0 0
Change From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP)
Timepoint [2] 0 0
Baseline, Week 12
Secondary outcome [3] 0 0
Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) =3.3
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
Mean Duration of Morning Joint Stiffness(MJS) in the Prior 7 Days as Collected in Electronic Daily Diaries
Timepoint [4] 0 0
Week 12
Secondary outcome [5] 0 0
Mean Severity of Morning Joint Stiffness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries
Timepoint [5] 0 0
Week 12
Secondary outcome [6] 0 0
Mean Worst Tiredness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries
Timepoint [6] 0 0
Week 12
Secondary outcome [7] 0 0
Mean Worst Joint Pain Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries
Timepoint [7] 0 0
Week 12
Secondary outcome [8] 0 0
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
Timepoint [8] 0 0
Week 12, Week 24
Secondary outcome [9] 0 0
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
Timepoint [9] 0 0
Week 12, Week 24
Secondary outcome [10] 0 0
Change From Baseline in Measures of Clinical Disease Activity Index (CDAI) Score
Timepoint [10] 0 0
Baseline, Week 24
Secondary outcome [11] 0 0
Change From Baseline in Measures of Simplified Disease Activity Index (SDAI) Score
Timepoint [11] 0 0
Baseline, Week 24
Secondary outcome [12] 0 0
Change From Baseline in DAS28-Erythrocyte Sedimentation Rate (DAS28-ESR)
Timepoint [12] 0 0
Baseline, Week 12
Secondary outcome [13] 0 0
Percentage of Participants Achieving American College of Rheumatology European League Against Rheumatism (ACR/EULAR) Remission - Boolean Remission
Timepoint [13] 0 0
Week 12
Secondary outcome [14] 0 0
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores.
Timepoint [14] 0 0
Baseline, Week 12; Baseline Week 24
Secondary outcome [15] 0 0
Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)
Timepoint [15] 0 0
Baseline, Week 12; Baseline, Week 24
Secondary outcome [16] 0 0
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores
Timepoint [16] 0 0
Baseline Week 12; Baseline Week 24
Secondary outcome [17] 0 0
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
Timepoint [17] 0 0
Baseline Week 12; Baseline Week 24
Secondary outcome [18] 0 0
Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores
Timepoint [18] 0 0
Baseline, Week 12; Baseline, Week 24
Secondary outcome [19] 0 0
Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104
Timepoint [19] 0 0
Week 0: 30 and 90 minutes postdose; Week 8: 1 hour postdose; Week 12, Week 20 and Week 24:predose
Secondary outcome [20] 0 0
Population PK: Maximum Concentration at Steady State of Dosing (AUC,ss) of LY3009104
Timepoint [20] 0 0
Week 0: 30 and 90 minutes postdose; Week 8: 1 hour postdose; Week 12, Week 20 and Week 24; predose

Eligibility
Key inclusion criteria
- Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) as defined by the American
College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria
for the Classification of RA

- Have moderately to severely active RA defined as the presence of at least 6/68 tender
joints and at least 6/66 swollen joints

- Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP)
measurement = (greater than or equal to) 1.2 times the upper limit of normal (ULN)

- Have had an insufficient response or are intolerant to conventional disease-modifying
antirheumatic drugs (cDMARDs) and either:

- Have had regular use of a cDMARD for at least the 12 weeks prior to study entry
with a continuous, nonchanging dose for at least 8 weeks prior to study entry

- For participants not receiving a cDMARD at the time of entry, the investigator
will document in the participant's history that the participant had failed, was
unable to tolerate, or had a contraindication to treatment with a cDMARD
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Are currently receiving corticosteroids at doses > (greater than)10 mg per day of
prednisone (or equivalent) or have been receiving an unstable dosing regimen of
corticosteroids within 2 weeks of study entry or within 6 weeks of planned
randomization

- Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have
been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or
within 6 weeks of planned randomization

- Are currently receiving concomitant treatment with methotrexate (MTX),
hydroxychloroquine, and sulfasalazine or combination of any 3 cDMARDs

- Have ever received any biologic DMARD

- Have received interferon therapy within 4 weeks prior to study entry or are
anticipated to require interferon therapy during the study

- Have received any parenteral corticosteroid administered by intramuscular or
intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior
to planned randomization or are anticipated to require parenteral injection of
corticosteroids during the study

- Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic
acid within 2 weeks prior to study entry or within 6 weeks prior to planned
randomization

- Have active fibromyalgia that, in the investigator's opinion, would make it difficult
to appropriately assess RA activity for the purposes of this study

- Have a diagnosis of any systemic inflammatory condition other than RA, such as, but
not limited to juvenile chronic arthritis,spondyloarthropathy, Crohn's disease,
ulcerative colitis, psoriatic arthritis, active vasculitis or gout(participants with
secondary Sjogren's syndrome are not excluded.)

- Have a diagnosis of Felty's syndrome

- Have had any major surgery within 8 weeks of study entry or will require major surgery
during the study that, in the opinion of the investigator in consultation with Lilly
or its designee, would pose an unacceptable risk to the participant

- Have experienced any of the following within 12 weeks of study entry: myocardial
infarction, unstable ischemic heart disease, stroke, or have New York Heart
Association stage IV heart failure

- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
endocrine, hematological, neurological, or neuropsychiatric disorders or any other
serious and/or unstable illness that, in the opinion of the investigator, could
constitute a risk when taking investigational product or could interfere with the
interpretation of data

- Are largely or wholly incapacitated permitting little or no self care, such as, being
bedridden or confined to a wheelchair

- Have an estimated glomerular filtration rate (eGFR) based on the most recent available
serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of <
(less than) 40 milliliter per minute per 1.73 m^2 (mL/min/1.73 m^2)

- Have a history of chronic liver disease with the most recent available aspartate
aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the
most recent available total bilirubin >/=1.5 times the ULN

- Have a history of, lymphoproliferative disease; or have signs or symptoms suggestive
of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or
have active primary or recurrent malignant disease; or have been in remission from
clinically significant malignancy for <5 years

- Have been exposed to a live vaccine within 12 weeks prior to planned randomization or
are expected to need/receive a live vaccine during the course of the study (with the
exception of herpes zoster vaccination)

- Have a current or recent clinically serious viral, bacterial, fungal, or parasitic
infection

- Have had symptomatic herpes zoster infection within 12 weeks prior to study entry

- Have a history of disseminated/complicated herpes zoster (eg, multidermatomal
involvement, ophthalmic zoster, central nervous system involvement, postherpetic
neuralgia)

- Are immunocompromised and, in the opinion of the investigator, are at an unacceptable
risk for participating in the study

- Have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human
immunodeficiency virus (HIV)

- Have screening laboratory test values, including thyroid-stimulating hormone (TSH),
outside the reference range for the population or investigative site that, in the
opinion of the investigator, pose an unacceptable risk for the participant's
participation in the study

- Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the
investigator or the sponsor, are clinically significant and indicate an unacceptable
risk for the participant's participation in the study (eg, Fridericia's corrected QT
interval >500 millisecond [msec] for men and >520 msec for women)

- Have symptomatic herpes simplex at the time of study enrollment

- Have evidence of active or latent tuberculosis (TB)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2014
Sample size
Target
Accrual to date
Final
684
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Camperdown
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Maroochydore
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
4558 - Maroochydore
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Delaware
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oklahoma
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Córdoba
Country [26] 0 0
Argentina
State/province [26] 0 0
Quilmes
Country [27] 0 0
Argentina
State/province [27] 0 0
Tucuman
Country [28] 0 0
Belgium
State/province [28] 0 0
Genk
Country [29] 0 0
Belgium
State/province [29] 0 0
Gent
Country [30] 0 0
Belgium
State/province [30] 0 0
Merksem
Country [31] 0 0
Belgium
State/province [31] 0 0
Mons
Country [32] 0 0
Canada
State/province [32] 0 0
British Columbia
Country [33] 0 0
Canada
State/province [33] 0 0
Manitoba
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Canada
State/province [36] 0 0
Saskatchewan
Country [37] 0 0
Croatia
State/province [37] 0 0
Karlovac
Country [38] 0 0
Croatia
State/province [38] 0 0
Osijek
Country [39] 0 0
Croatia
State/province [39] 0 0
Varazdin
Country [40] 0 0
Croatia
State/province [40] 0 0
Zagreb
Country [41] 0 0
Czechia
State/province [41] 0 0
Brno
Country [42] 0 0
Czechia
State/province [42] 0 0
Hustopece
Country [43] 0 0
Czechia
State/province [43] 0 0
Pardubice
Country [44] 0 0
Czechia
State/province [44] 0 0
Uherske Hradiste
Country [45] 0 0
Germany
State/province [45] 0 0
Gommern
Country [46] 0 0
Germany
State/province [46] 0 0
Köln
Country [47] 0 0
Germany
State/province [47] 0 0
Würzburg
Country [48] 0 0
Hungary
State/province [48] 0 0
Bekescsaba
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Debrecen
Country [51] 0 0
Hungary
State/province [51] 0 0
Szekesfehervar
Country [52] 0 0
Hungary
State/province [52] 0 0
Veszprem
Country [53] 0 0
India
State/province [53] 0 0
Ahmedabad
Country [54] 0 0
India
State/province [54] 0 0
Attavar, Mangalore
Country [55] 0 0
India
State/province [55] 0 0
Bangalore
Country [56] 0 0
India
State/province [56] 0 0
Belgaum
Country [57] 0 0
India
State/province [57] 0 0
Gurgaon
Country [58] 0 0
India
State/province [58] 0 0
Hyderabaad
Country [59] 0 0
India
State/province [59] 0 0
Jaipur
Country [60] 0 0
India
State/province [60] 0 0
Kolkata
Country [61] 0 0
India
State/province [61] 0 0
Lucknow
Country [62] 0 0
India
State/province [62] 0 0
Mumbai
Country [63] 0 0
India
State/province [63] 0 0
Secunderabad
Country [64] 0 0
Italy
State/province [64] 0 0
Milano
Country [65] 0 0
Italy
State/province [65] 0 0
Prato
Country [66] 0 0
Italy
State/province [66] 0 0
Rozzano
Country [67] 0 0
Italy
State/province [67] 0 0
Valeggio Sul Mincio
Country [68] 0 0
Japan
State/province [68] 0 0
Aichi
Country [69] 0 0
Japan
State/province [69] 0 0
Hiroshima
Country [70] 0 0
Japan
State/province [70] 0 0
Hokkaido
Country [71] 0 0
Japan
State/province [71] 0 0
Kagawa
Country [72] 0 0
Japan
State/province [72] 0 0
Okayama
Country [73] 0 0
Japan
State/province [73] 0 0
Saitama
Country [74] 0 0
Japan
State/province [74] 0 0
Tochigi
Country [75] 0 0
Japan
State/province [75] 0 0
Tokyo
Country [76] 0 0
Japan
State/province [76] 0 0
Toyama
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Gwangju
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Incheon
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Seoul
Country [80] 0 0
Mexico
State/province [80] 0 0
Mexicali
Country [81] 0 0
Mexico
State/province [81] 0 0
Mexico City
Country [82] 0 0
Poland
State/province [82] 0 0
Bydgoszcz
Country [83] 0 0
Poland
State/province [83] 0 0
Elblag
Country [84] 0 0
Poland
State/province [84] 0 0
Gdansk
Country [85] 0 0
Poland
State/province [85] 0 0
Lodz
Country [86] 0 0
Poland
State/province [86] 0 0
Nadarzyn
Country [87] 0 0
Portugal
State/province [87] 0 0
Almada
Country [88] 0 0
Portugal
State/province [88] 0 0
Ponte De Lima
Country [89] 0 0
Puerto Rico
State/province [89] 0 0
Caguas
Country [90] 0 0
Puerto Rico
State/province [90] 0 0
San German
Country [91] 0 0
Puerto Rico
State/province [91] 0 0
San Juan
Country [92] 0 0
Puerto Rico
State/province [92] 0 0
Santurce
Country [93] 0 0
Romania
State/province [93] 0 0
Bucharest
Country [94] 0 0
Romania
State/province [94] 0 0
Cluj-Napoca
Country [95] 0 0
Romania
State/province [95] 0 0
Constanta
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Moscow
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Saint Petersburg
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Ulyanovsk
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Yaroslavl
Country [100] 0 0
Slovakia
State/province [100] 0 0
Bratislava
Country [101] 0 0
Slovakia
State/province [101] 0 0
Partizanske
Country [102] 0 0
Slovakia
State/province [102] 0 0
Topolcany
Country [103] 0 0
Spain
State/province [103] 0 0
Bilbao
Country [104] 0 0
Spain
State/province [104] 0 0
Getafe
Country [105] 0 0
Spain
State/province [105] 0 0
Santander
Country [106] 0 0
Spain
State/province [106] 0 0
Valencia
Country [107] 0 0
Spain
State/province [107] 0 0
Villajoyosa
Country [108] 0 0
Taiwan
State/province [108] 0 0
Kaohsiung City
Country [109] 0 0
Taiwan
State/province [109] 0 0
Neihu Taipei
Country [110] 0 0
Taiwan
State/province [110] 0 0
Taichung City
Country [111] 0 0
Taiwan
State/province [111] 0 0
Taichung
Country [112] 0 0
Taiwan
State/province [112] 0 0
Taipei
Country [113] 0 0
Taiwan
State/province [113] 0 0
Yong Kung City
Country [114] 0 0
United Kingdom
State/province [114] 0 0
England
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Hampshire
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Tyneside

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily
(QD) is superior to placebo in the treatment of participants with moderately to severely
active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at
least 1 conventional disease-modifying antirheumatic drug (cDMARD)(cDMARD-IR [inadequate
response] participants) and who have not received a biologic disease-modifying antirheumatic
drug (DMARD).
Trial website
https://clinicaltrials.gov/ct2/show/NCT01721057
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01721057